NEW YORK, Sept. 22 (GenomeWeb News) - Galapagos Genomics has split its business into a drug discovery and a research service unit, the Mechelen, Belgium-based company said today.
The service unit will operate under the name Galadeno from the company's facility in Leiden. It will offer both individual adenovirus-based siRNA and full-length gene reagents for drug target discovery and validation. Galadeno will also provide access to its cDNA collection FlexSelect and its siRNA collection SilenceSelect, and will continue to offer a human primary cell-based functional screening platform to partners.
The drug discovery business will continue to operate under the name Galapagos and will be located at the company's Mechelen facility.
"[T]his separation will allow each unit to grow in a dedicated way," said Galapagos CEO Onno van de Stolpe in a statement.